MorphoSys Group
On March 1, 2012 MorphoSys published its Year-End results for 2011 and published its financial guidance for 2012. For 2012, MorphoSys anticipates total Group revenues between EUR 75 million and EUR 80 million and anticipates an EBIT in the range of EUR 1 million to EUR 5 million. This guidance does not, at this stage, include a successful out-licensing of any of the Company's proprietary development programs. Investment in proprietary research and development in 2012 will be approximately EUR 20-25 million.
| in € million | 2012 | 2011 |
| Group Revenues | 75 - 80 | 100.8 |
| Investment in Proprietary R&D | 20 - 25 | 36.7 |
| Group EBIT | 1 - 5 | 11.1 |
